Cantabio Pharmaceuticals, Inc. announced that The Michael J. Fox Foundation for Parkinson’s Research has awarded the Company a major grant entitled “Quantification of Cys106 of DJ-1 in Distinct Redox States in Parkinson’s Patients’ iPSC-derived Dopaminergic Neurons, Postmortem Brain Tissue and Plasma as a Potential Biomarker of Parkinson’s Disease”.
